Practitioner's Docket No. U 015825-1

**PATENT** 

. *V* 5

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rafael ROSELL COSTA, et al.

Serial No.: 10/540,047

Group No.: --

Filed: December 29, 2003

Examiner: --

For: DEVICE FOR ASSAYING POLYMORPHISMS OF GENE XPD/ERCC2 FOR THE CORRECT

ADMINISTRATION OF CHEMOTHERAPY FOR LUNG CANGER

Mail Stop Sequence Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

> SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

### CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10\*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

#### **MAILING**

	deposited with the United States Postal Service in an envelope ad Alexandria, VA 22313-1450.	Idressed to the Commissioner for Patents, P. O. Box 1450,
	37 C.F.R. 1.8(a)	37 C.F.R. 1.10*
	with sufficient postage as first class mail.  TRANSMISSI	as "Express Mail Post Office to Address"  Mailing Label No. <u>EV480462141US</u> (mandatory)  ON
	transmitted by facsimile to the Patent and Trademark Office. to	Gualdine Maite
Date: November 10, 2005		Geraldine Marti (type or print name of person certifying)

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(check and complete this item, if applicable)

1. [X] This replies to the Office Letter dated November 2, 2005

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added.

[X] A copy of the Office Letter is enclosed.

### IDENTIFICATION OF PERSON MAKING STATEMENT

	(type or print name of person signing below)
	state the following:
	ITEMS BEING SUBMITTED
3.	Submitted herewith is/are
	(check each item as applicable)
	A. [X] "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. 1.821(c) and 37 C.F.R. 1.822 and 1.823.
	B. [] An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. 1.821(d).
	C. [X] A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. 1.821(e) and 1.824.
	D. [ ] Please transfer to this application, in accordance with 37 C.F.R. 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

(Submission-Nucleotide and/or Amino Acid Sequence—page 2 of 6) 9-37

In i	re application of:		
	Serial No.:	Group No.:	
	Filed:	Examiner:	
	For:		
	e Computer readable form(s nce Identifier(s)" of this app	s) of applicant's other application corresponds or compa blication as follows:	ires to the
Compu	ter Readable Form	"Sequence 1	Identifier"
	applications)	(this ap	oplication)
NOTE:	application of the applicant on j readable form in lieu of filing a d	of a new application is to be identical with the computer readable form file in the Office, reference may be made to the other application and luplicate computer readable form in the new application. The new application and computer readable form, b of C.F.R. 1.821(e).	nd computer lication shal
E.		content of each "Sequence Listing" submitted and each same, as required in 37 C.F.R. 1.821(f).	computer
		nent is not made by a person registered to practice before to prified as required in 37 C.F.R. 1.821(b).	he Office
F.		on is made in fulfilling the requirement under 37 C.F.R. 1 nission includes no new matter.	.821(g), a
		nent is not made by a person registered to practice before trified, as required in 37 C.F.R. 1.821(g).	the Office
	AND COMPU	MENT THAT "SEQUENCE LISTING" UTER READABLE COPY ARE THE SAME ERS SUBMITTED INCLUDES NO NEW MATTER	

4. I hereby state:

(complete applicable item A and/or B)

- A. [X] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. [X] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

(Submission-Nucleotide and/or Amino Acid Sequence—page 3 of 6) 9-37

## **STATUS**

5.	Аp	oplicant is			
	[X] a small entity:				
	[]	other than a small entity.			
		EXTENSION OF TERM			
6. NOTE:		37 C.F.R. § 1.704(b)" an applicant processing or examination of an applicathat are taken to reply to any notice of request, measuring such three-month pein which case the period of adjustment son the day after the date that is three montifying the applicant of the rejection, filed. The period, or shortened statutory three-month period set forth in this para	tion for the cumulative total of any peri- caction by the Office making any reject riod from the date the notice or action v et forth in § 1.703 shall be reduced by the onths after the date of mailing or transmobjection, argument, or other request a period, for reply that is set in the Office	ods of time in excess of three monthetion, objection, argument, or othe vas mailed or given to the applicanthe he number of days, if any, beginning mission of the Office communication and ending on the date the reply wa	
NOTE:		"Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed afte a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.			
		If a timely response has been filed after a entry of a Notice of Appeal or filing a statutory period unless the timely-filed Notice of Appeal has been filed within the 1985 (1061 O.G. 34-35).	nd/or entry of an additional amendme response placed the application in cond	nt after expiration of the shortene dition for allowance. Of course, if	
NO	TE:	See 37 C.F.R. 1.645 for extensions of tinin reexamination proceedings.	ne in interference proceedings and 37 C	F.R. 1.550(c) for extensions of tim	
7.	7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply.				
		(compl	ete (a) or (b) as applicable)		
(a) [ ] Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R 1.17(a)(1)-(4)) for the total number of months checked below:					
		Extension (months)	Fee for other than small entity	Fee for small entity	
		[ ] one month [ ] two months [ ] three months [ ] four months	\$120.00 \$450.00 \$1,020.00 \$1,590.00	\$60.00 \$225.00 \$510.00 \$795.00	

If an additional extension of time is required, please consider this a petition therefor.

Fee \$ \_\_\_\_\_

		(check and complete the next item, if applicable)
		[ ] An extension for months has already been secured, and the fee paid therefor of \$ is deducted from the total fee due for the total months of extension now requested.
		Extension fee due with this request \$
		OR
	(b)	[X] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.
		FEE PAYMENT
8.	[]	Attached is a check in the sum of \$
	[]	Charge Account No the sum of \$  A duplicate of this transmittal is attached.
		FEE DEFICIENCY
9. <i>NOT</i>	E:	If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.

10. [X] If any additional extension and/or fee is required, charge Account No. 12-0425.

(Submission-Nucleotide and/or Amino Acid Sequence—page 5 of 6) 9-37

# SIGNATURE(s)

	(type or print name of person signing statement)
	Signature
Date	
P.O. Address of Signatory	
(If applicable)	Inventor     Assignee of complete interest     Person authorized to sign on behalf of
Tel. No.: ( ) Reg. No.	assignee [ ] Practitioner of record [ ] Filed under Rule 34(a) [ ] Registration No [ ] Other (specify identity of person signing)
(complete the following, if a	applicable)
(type name of assignee)	
Address of assignee	
Title of person authorized to sign on behalf of assignee	
A "STATEMENT UNDER 37 C.F.R. 3.73(b)" is attached.	
Assignment recorded in PTO on Reel Frame	SIGNATURE OF PRACTITIONER
Reg. No. 33,778	Janet I. Cord (type or print name of practitioner)
Tel. No.: (212)708-1935	P.O. Address
	c/o Ladas & Parry LLP 26 West 61 <sup>st</sup> Street New York, N.Y. 10023

Customer No.:

00140

PATENT TRADEMARK OFFICE